Utah Medical Products Stock-Based Compensation Growth & History (UTMD)
Utah Medical Products's stock-based compensation was $373,000 for fiscal 2025.
View full Utah Medical Products company overviewUtah Medical Products annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $373,000 | $117,000 | +45.70% |
| 2024 | 2024-12-31 | $256,000 | $31,000 | +13.78% |
| 2023 | 2023-12-31 | $225,000 | $42,000 | +22.95% |
| 2022 | 2022-12-31 | $183,000 | $17,000 | +10.24% |
| 2021 | 2021-12-31 | $166,000 | $6,000 | +3.75% |
| 2020 | 2020-12-31 | $160,000 | $47,000 | +41.59% |
| 2019 | 2019-12-31 | $113,000 | $49,000 | +76.56% |
| 2018 | 2018-12-31 | $64,000 | −$65,000 | −50.39% |
| 2017 | 2017-12-31 | $129,000 | $37,000 | +40.22% |
| 2016 | 2016-12-31 | $92,000 | $5,000 | +5.75% |
| 2015 | 2015-12-31 | $87,000 | $13,000 | +17.57% |
| 2014 | 2014-12-31 | $74,000 | $46,000 | +164.29% |
| 2013 | 2013-12-31 | $28,000 | −$42,000 | −60.00% |
| 2012 | 2012-12-31 | $70,000 | −$25,000 | −26.32% |
| 2011 | 2011-12-31 | $95,000 | $12,000 | +14.46% |
| 2010 | 2010-12-31 | $83,000 | −$15,000 | −15.31% |
| 2009 | 2009-12-31 | $98,000 | — | — |
Utah Medical Products quarterly stock-based compensation
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $72,000 | −$14,000 | −16.28% |
| Q1 2026 | 2026-03-31 | $120,000 | $38,000 | +46.34% |
| Q4 2025 | 2025-12-31 | $111,000 | $39,000 | +54.17% |
| Q3 2025 | 2025-09-30 | $94,000 | $41,000 | +77.36% |
| Q2 2025 | 2025-06-30 | $86,000 | $34,000 | +65.38% |
| Q1 2025 | 2025-03-31 | $82,000 | $3,000 | +3.80% |
| Q4 2024 | 2024-12-31 | $72,000 | $0 | 0.00% |
| Q3 2024 | 2024-09-30 | $53,000 | $0 | 0.00% |
| Q2 2024 | 2024-06-30 | $52,000 | $2,000 | +4.00% |
| Q1 2024 | 2024-03-31 | $79,000 | $29,000 | +58.00% |
| Q4 2023 | 2023-12-31 | $72,000 | $10,000 | +16.13% |
| Q3 2023 | 2023-09-30 | $53,000 | $15,000 | +39.47% |
| Q2 2023 | 2023-06-30 | $50,000 | $10,000 | +25.00% |
| Q1 2023 | 2023-03-31 | $50,000 | $7,000 | +16.28% |
| Q4 2022 | 2022-12-31 | $62,000 | $19,000 | +44.19% |
| Q3 2022 | 2022-09-30 | $38,000 | −$3,000 | −7.32% |
| Q2 2022 | 2022-06-30 | $40,000 | −$1,000 | −2.44% |
| Q1 2022 | 2022-03-31 | $43,000 | $2,000 | +4.88% |
| Q4 2021 | 2021-12-31 | $43,000 | $4,000 | +10.26% |
| Q3 2021 | 2021-09-30 | $41,000 | −$8,000 | −16.33% |
| Q2 2021 | 2021-06-30 | $41,000 | −$8,000 | −16.33% |
| Q1 2021 | 2021-03-31 | $41,000 | $18,000 | +78.26% |
| Q4 2020 | 2020-12-31 | $39,000 | $11,000 | +39.29% |
| Q3 2020 | 2020-09-30 | $49,000 | $20,000 | +68.97% |
| Q2 2020 | 2020-06-30 | $49,000 | $21,000 | +75.00% |
| Q1 2020 | 2020-03-31 | $23,000 | −$5,000 | −17.86% |
| Q4 2019 | 2019-12-31 | $28,000 | $17,000 | +154.55% |
| Q3 2019 | 2019-09-30 | $29,000 | $18,000 | +163.64% |
| Q2 2019 | 2019-06-30 | $28,000 | $16,000 | +133.33% |
| Q1 2019 | 2019-03-31 | $28,000 | −$2,000 | −6.67% |
| Q4 2018 | 2018-12-31 | $11,000 | −$19,000 | −63.33% |
| Q3 2018 | 2018-09-30 | $11,000 | −$19,000 | −63.33% |
| Q2 2018 | 2018-06-30 | $12,000 | −$21,000 | −63.64% |
| Q1 2018 | 2018-03-31 | $30,000 | −$6,000 | −16.67% |
| Q4 2017 | 2017-12-31 | $30,000 | $0 | 0.00% |
| Q3 2017 | 2017-09-30 | $30,000 | $10,000 | +50.00% |
| Q2 2017 | 2017-06-30 | $33,000 | $12,000 | +57.14% |
| Q1 2017 | 2017-03-31 | $36,000 | $15,000 | +71.43% |
| Q4 2016 | 2016-12-31 | $30,000 | $9,000 | +42.86% |
| Q3 2016 | 2016-09-30 | $20,000 | −$2,000 | −9.09% |
| Q2 2016 | 2016-06-30 | $21,000 | −$1,000 | −4.55% |
| Q1 2016 | 2016-03-31 | $21,000 | −$1,000 | −4.55% |
| Q4 2015 | 2015-12-31 | $21,000 | −$4,000 | −16.00% |
| Q3 2015 | 2015-09-30 | $22,000 | −$3,000 | −12.00% |
| Q2 2015 | 2015-06-30 | $22,000 | $4,000 | +22.22% |
| Q1 2015 | 2015-03-31 | $22,000 | $16,000 | +266.67% |
| Q4 2014 | 2014-12-31 | $25,000 | $18,000 | +257.14% |
| Q3 2014 | 2014-09-30 | $25,000 | $18,000 | +257.14% |
| Q2 2014 | 2014-06-30 | $18,000 | $11,000 | +157.14% |
| Q1 2014 | 2014-03-31 | $6,000 | −$1,000 | −14.29% |
| Q4 2013 | 2013-12-31 | $7,000 | −$9,000 | −56.25% |
| Q3 2013 | 2013-09-30 | $7,000 | −$9,000 | −56.25% |
| Q2 2013 | 2013-06-30 | $7,000 | −$11,000 | −61.11% |
| Q1 2013 | 2013-03-31 | $7,000 | −$13,000 | −65.00% |
| Q4 2012 | 2012-12-31 | $16,000 | −$6,000 | −27.27% |
| Q3 2012 | 2012-09-30 | $16,000 | −$8,000 | −33.33% |
| Q2 2012 | 2012-06-30 | $18,000 | −$7,000 | −28.00% |
| Q1 2012 | 2012-03-31 | $20,000 | −$4,000 | −16.67% |
| Q4 2011 | 2011-12-31 | $22,000 | — | — |
| Q3 2011 | 2011-09-30 | $24,000 | $4,000 | +20.00% |
| Q2 2011 | 2011-06-30 | $25,000 | — | — |
| Q1 2011 | 2011-03-31 | $24,000 | — | — |
| Q3 2010 | 2010-09-30 | $20,000 | — | — |
Utah Medical Products stock-based compensation trends
Over the last five fiscal years, Utah Medical Products's stock-based compensation increased from $160,000 to $373,000, a change of $213,000. The latest reported quarter, Q2 2026, shows $72,000.
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Utah Medical Products source filings ↗